logo
logo

Oxford-Based Ultromics Secures £23.7M To Help Doctors Diagnose Cardiovascular Disease Through Ai

Aug 16, 2021•almost 4 years ago

Amount Raised

£23.7 Million

Oxford

Description

Cardiovascular disease is the leading cause of mortality globally, with an estimated 17 million deaths each year. Thanks to development in medical technology and clinical research, imaging tests and diagnostic measurements are constantly evolving, particularly in cardiology.

Company Information

Company

Oxford Based Ultromics

Location

Oxford, Mississippi, United States

About

Recently, the UK company has secured $33 million (approx £23.7 million) in a Series B funding round led by Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation.“Cardiovascular disease is the leading cause of morbidity and mortality in the United States, and Ultromics offers groundbreaking AI solutions for more accurate diagnosis,” said Dr. Emir Sandhu, Managing Director at the Blue Venture Fund. “We are excited to partner with Dr. Ross Upton and the Ultromics’ team, as they promote improved patient outcomes.”The company will use the funding to help accelerate the use of AI-enabled echocardiograms to help improve patient care and bring improved diagnostic quality and resource savings to hospitals.Echocardiography-based solutionsFounded in 2017 by Ross Upton and Paul Leeson, Ultromics is a spin-off of the University of Oxford and built-in partnership with the UK’s NHS. The company has developed the first fully automated solution for echocardiography (EchoGo Core and EchoGo Pro) and analysis of global longitudinal strain (GLS).

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech